TrialmBio2022

Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing Antibodies.

Andrea T Hooper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.